Cadila Pharmaceuticals launched Mycidac-C, a lung cancer drug

Nov 22, 2013 11:11 IST

Cadila Pharmaceuticals on 21 November 2013 launched a new lung cancer drug, Mycidac-C, which is priced 40000 rupees for 10 course injection. The drug is much cheaper than the drugs manufactured by the multinational companies.

Cadila developed the drug after 15 years research and it will be available in Indian market from December 2013. Mycidac-C has been licensed and approved by the Drug Controller General of India (DCGI). The drug, Mycidac-C is meant for the patients, who suffer from non-small cell lung cancer (NSCLC).

If you have any Question/Point on the above information, please ask/discuss it in the Current Affairs Group

Is this article important for exams ? Yes6 People Agreed
Read more Current Affairs on: Cadila Pharmaceuticals , Mycidac-C , Lung Cancer drug

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK